---
title: "Incyte Corporation Reports 2024 Financial Results and 2025 Guidance"
date: "2025-02-10 20:05:00"
summary: "Incyte Corporation, a global biopharmaceutical company, has released its financial results for the fourth quarter and full year ending December 31, 2024. The company also provided its financial guidance for 2025, highlighting significant growth and strategic milestones. Financial Highlights Incyte reported total revenues of $1.2 billion for the fourth quarter..."
categories:
  - "TradingView"
lang:
  - "en"
translations:
  - "en"
tags:
  - "TradingView"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Incyte Corporation, a global biopharmaceutical company, has released its financial results for the fourth quarter and full year ending December 31, 2024. The company also provided its financial guidance for 2025, highlighting significant growth and strategic milestones.

**Financial Highlights**

Incyte reported total revenues of $1.2 billion for the fourth quarter of 2024, marking a 16% year-over-year increase. For the full year 2024, total revenues reached $4.2 billion, a 15% increase compared to 2023. Key financial metrics include:

* **GAAP Net Income:** $201.2 million for Q4 2024, consistent with Q4 2023. For the full year, GAAP net income was $32.6 million, down from $597.6 million in 2023.
* **Non-GAAP Net Income:** $281.4 million for Q4 2024, up from $239.1 million in Q4 2023. For the full year, non-GAAP net income was $227.6 million, compared to $795.4 million in 2023.
* **GAAP Diluted EPS:** $1.02 for Q4 2024, compared to $0.89 in Q4 2023. For the full year, GAAP diluted EPS was $0.15, down from $2.65 in 2023.
* **Non-GAAP Diluted EPS:** $1.43 for Q4 2024, up from $1.06 in Q4 2023. For the full year, non-GAAP diluted EPS was $1.08, compared to $3.52 in 2023.

**Business and Operational Highlights**

Incyte's performance was driven by strong sales of its key products:

* **Jakafi® (ruxolitinib):** Net revenues of $773 million for Q4 2024, an 11% increase year-over-year. Full year net revenues were $2.8 billion, up 8% from 2023.
* **Opzelura® (ruxolitinib) cream:** Net revenues of $162 million for Q4 2024, a 48% increase year-over-year. Full year net revenues were $508 million, up 50% from 2023.
* **Minjuvi/Monjuvi:** Net revenues increased by 265% for Q4 2024 and 222% for the full year, driven by the acquisition of exclusive global rights for tafasitamab.

**Strategic Initiatives and Corporate Developments**

Incyte highlighted several strategic initiatives and corporate developments:

* Completion of a bioequivalence study for ruxolitinib extended-release (XR), with data submission to the FDA expected by year-end 2025.
* FDA approval of Niktimvo™ (axatilimab-csfr) in January 2025, with commercial launch underway in the U.S.
* Initiation of a Phase 3 monotherapy study for the BET inhibitor (INCB057643) in relapsed or refractory myelofibrosis.
* Submission of a supplemental Biologics License Application (sBLA) for retifanlimab (Zynyz®) in advanced/metastatic squamous cell anal carcinoma, with approval anticipated in the second half of 2025.

**Management's Perspective**

Hervé Hoppenot, Chief Executive Officer of Incyte, commented, "2024 was an important year for Incyte, with a 15% increase in total revenues, driven by strong growth from both Jakafi and Opzelura, as well as significant progress across our R&D pipeline. Looking ahead to 2025, we anticipate a year of continued strong revenue growth and diversification, as well as several defining milestones that will serve as an inflection point for Incyte."

**Future Outlook**

Incyte provided its financial guidance for 2025, projecting:

* **Jakafi net product revenues:** $2,925 - $2,975 million
* **Opzelura net product revenues:** $630 - $670 million
* **Other oncology net product revenues:** $415 - $455 million
* **GAAP Research and development expenses:** $1,930 - $1,960 million
* **Non-GAAP Research and development expenses:** $1,780 - $1,805 million

SEC Filing: [INCYTE CORP [ INCY ] - 8-K - Feb. 10, 2025](https://www.sec.gov/Archives/edgar/data/879169/000162828025004514/incy-20250210.htm)

[TradingView](https://www.tradingview.com/news/tradingview:47a6047a16e98:0-incyte-corporation-reports-2024-financial-results-and-2025-guidance/)
